Point72 Hong Kong’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-7,200
Closed -$2.33M 968
2022
Q3
$2.33M Buy
7,200
+4,700
+188% +$1.49M 0.08% 315
2022
Q2
$811K Sell
2,500
-500
-17% -$150K 0.03% 584
2022
Q1
$859K Sell
3,000
-5,500
-65% -$1.42M 0.03% 564
2021
Q4
$2.35M Sell
8,500
-9,400
-53% -$2.38M 0.08% 289
2021
Q3
$4.14M Sell
17,900
-13,700
-43% -$3.38M 0.13% 176
2021
Q2
$7.25M Buy
31,600
+9,900
+46% +$1.99M 0.24% 62
2021
Q1
$4.05M Sell
21,700
-10,200
-32% -$2M 0.14% 171
2020
Q4
$5.39M Buy
+31,900
New +$4.76M 0.24% 75

Other funds holding LLY

Point72 Hong Kong's LLY Position: Q3 2025 in Review

Point72 Hong Kong increased its Eli Lilly (LLY) stake by 17% in Q3 2025, buying an estimated $642K and bringing the position to 5,866 shares worth $4.48M. The position accounts for 0.21% of the portfolio, ranked #90.

Point72 Hong Kong first reported a position in LLY in Q3 2014 and has held it in 25 quarters since. The position peaked at $23M in Q3 2024. 3,898 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

  • Point72 Hong Kong held 5,866 shares of Eli Lilly worth $4.48M as of Q3 2025.
  • Point72 Hong Kong bought 863 Eli Lilly shares in Q3 2025, an estimated $642K.
  • Eli Lilly made up 0.21% of Point72 Hong Kong's portfolio in Q3 2025, its #90 holding.
  • Point72 Hong Kong first reported a position in Eli Lilly in Q3 2014 and has held it in 25 quarters since.
  • Point72 Hong Kong's Eli Lilly position peaked at $23M in Q3 2024.
  • 3,898 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.